anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells
/ National Cancer Institute
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
August 05, 2012
Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
(clinicaltrials.gov)
- P1; N=0; Withdrawn; Sponsor: Barbara Ann Karmanos Cancer Institute; N=30 ➔ 0
Clinical • Enrollment change • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • CD20
August 05, 2012
Donor T Cells, Low-Dose Aldesleukin, and Low-Dose GM-CSF After Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
(clinicaltrials.gov)
- P1; N=0; Withdrawn; Sponsor: Barbara Ann Karmanos Cancer Institute; Completed ➔ Withdrawn
Clinical • Trial withdrawal • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • CD20
1 to 2
Of
2
Go to page
1